[Portal vein thrombosis associated with a myeloproliferative disorder, prothrombin G20210A mutation, antiphospholipid syndrome, with repermeation during anticoagulant therapy].
Portal vein thrombosis, except in hepatocellular carcinoma and severe cirrhosis, is due to one or several prothrombotic disorders with or without a local precipitating factor. We report a case of a portal and splenic vein thrombosis, without cavernoma and varices which occurred in a 72-year-old man with abdominal pain and weakness. Three prothrombotic states including latent myeloproliferative disorder, antiphospholipid syndrome, and factor II G202101 mutation, were observed. Anticoagulant treatment resulted in complete repermeation of the portal and splenic veins without a hemorrhagic event. This illustrates that several prothrombotic states may occur in a single patient with portal vein thrombosis. Early anticoagulant therapy, in recent portal vein thrombosis, can result in repermeation.
Diaz
E
E
Service d'Hépato-Gastroentérologie, Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France.
Nahon
S
S
Charachon
A
A
Traissac
L
L
Lenoble
M
M
Challier
E
E
Delas
N
N
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000150:complications*; D006801:Humans; D008297:Male; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000150:complications*; D011169:Portal Vein; D011516:Prothrombin / Q000235:genetics*; D013162:Splenic Vein; D014057:Tomography, X-Ray Computed; D020246:Venous Thrombosis / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics
D000925:Anticoagulants; D011516:Prothrombin
Thrombose portale récente régressive sous anticoagulants secondaire à un syndrome myéloprolifératif latent, une mutation G20210A du gène de la prothrombine et un syndrome des antiphospholipides.